Mohammed M. Aboudeif: The Decision-Making Process for Anticoagulation in Stroke
Mohammed M. Aboudeif, Critical Care Registrar at King AbdulAziz University, shared on LinkedIn:
”Timing is often the most critical factor in neurocritical care, especially when balancing the risk of recurrent ischemia against the threat of hemorrhagic transformation.
Standardizing the transition from acute management to long-term prevention is essential for patient safety and clinical excellence.
This visual guide breaks down the decision-making process for Anticoagulation in Stroke, specifically focusing on the initiation of DOACs in patients with Atrial Fibrillation (AF).
Key Takeaways for the Clinical Team:
- The Acute Phase (0-48h): A universal ‘No’ for anticoagulation.
- The focus remains on stabilization, hydration, and DVT prophylaxis (IPC preferred).
Ischemic Stroke and AF
The 1-3-6-12 Rule remains a vital framework for starting DOACs based on stroke severity:
- Day 1: TIA
- Day 3: Mild (NIHSS <8)
- Day 6: Moderate (NIHSS 8-15)
- Day 12: Severe (NIHSS >15)
Hemorrhagic Stroke: A much more conservative approach.
Restarting anticoagulation is generally deferred for 2–4 weeks and reserved for those with high embolic risk (e.g., mechanical valves), requiring careful reassessment of re-bleeding risk.
Standardized protocols like these reduce clinical variability and improve outcomes in the ICU and beyond.”
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 16:28Jon Douglas: Imperial College London Review Maps Key Pathways in Autoimmune Thrombosis
-
Sep 5, 2026, 16:21Kelly Anderson: Bilateral Foot Pain and Purple Toes – Spotting Vascular Complications in Polycythemia Vera
-
Sep 5, 2026, 16:16Hazem Abosheaishaa: Beta-Blocker Selection Matters – Multi-Institutional Cohort Insights on PVT and Survival in Cirrhosis
-
Sep 5, 2026, 16:08Indre Ceponiene: Major Gaps in Secondary Cardiovascular Prevention Across Europe
-
Sep 5, 2026, 16:03W. Alberto Sifuentes Giraldo: Why Obstetric Cases Are Missed Under 2023 ACR/EULAR APS Criteria
-
Sep 5, 2026, 15:58Srikanth Nalla: A Case of Saddle Pulmonary Embolism
-
Sep 5, 2026, 15:55COPD-specific Pulmonary Embolism Diagnostic Strategy – Thrombosis and Haemostasis
-
Sep 5, 2026, 15:41Sam Tsimikas on Lp(a) HORIZON Topline Results – What Missed Endpoints Mean for Cardiovascular Risk
-
Sep 5, 2026, 15:32Stefano Garzon: SELUTION DeNovo HBR – Weren’t HBR Patients Supposed to Bleed More with DES?